PointCross offers SDIS technology to BioPharma industry
SDIS is a solution that closes a major gap in the nonclinical phase of the R&D lifecycle and also creates an instantly searchable resource of all nonclinical study
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Of the additional sites, the Stanford Cancer Center (Stanford, California) under principal investigator Jason Gotlib, has already commenced enrolling patients, additionally the company will start recruiting patients in
Synthon has also completed registration procedures for Tamsulosin, reported PharmaLive.com. Tamsulosin, an a1a-selective alpha blocker, contains the active ingredient Tamsulosin hydrochloride. Developed by Yamanouchi Pharmaceuticals (now part of